N/A N=12 Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection
Urinary Tract Infections
Primary: Prevalence of Urinary Tract Infections (UTI) — 28.6; 60; 71.4; 40 percentage of subjects — p=0.034
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Effects of Sensory Flicker and Electrical Flicker Stimulation
Brain Diseases
Primary: Fold-change in Oscillatory Activity (Power Spectral Density) in Response to Exposure to Sensory Flicker: Comparing Mean Power Spectral Density at the Frequency of…
Phase 2 N=72 Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?
Congenital Heart Defects
Primary: S-creatinine — 23.9; 25.9; 33.7; 34.2 μmol/L — p=0.45
Phase 4 N=19 Treatment of Keloids With Fractional Erbium Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid
Keloid Scar
Primary: Change in Patient and Observer Scar Assessment Scale (POSAS) Score From Baseline to Final Visit — -20; -20.6 score on a scale
N/A N=83 A Trauma-Informed Intervention for Positive Youth Development and Teacher Wellness in Rural Montana Year 2
Trauma and Stressor Related Disorders
Primary: Salivary Cortisol Levels — .33; .25; .15; .30 micrograms per deciliter
Phase 3 N=50 A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
Primary: Lactate Dehydrogenase (U/L) at Week 26 — 284.20; 249.72 U/L
N/A N=30 Switching to Potential Reduced Exposure Products in Adult Smokers
Tobacco Use Disorder · Oral Nicotine Pouch Use · Smoking Behaviors
Primary: Number of Cigarettes Smoked Per Day (Log-transformed) — 2.0; 1.8 number of cigarettes smoked
Phase 2 N=20 Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
Neuroendocrine Tumors · Neuroendocrine Carcinoma · Neuroendocrine Cancer
Primary: Objective Radiographic Response Rate (ORR) — .1 proportion of participants
N/A N=60 The Intrepid Clinical Engineering Study
Sudden Cardiac Arrest
Primary: Validation of Algorithm Software Update — 0; 0; 0 Participants
N/A N=11 Clinical Study to Evaluate the Sun Protection Factor (SPF) of Sunscreen Products
Sunscreening Agents
Primary: Arithmetic Mean SPF Values — 13.9; 16.1; 14.3; 15.8 Ratio
Phase 1 N=15 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder
Autistic Disorder
Primary: Adverse Event of Special Interest (AESIs) and Adverse Events (AEs) Leading to Discontinuation — 0; 0; 1; 2 adverse events
Phase 3 N=23 Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department
Acute Musculoskeletal Disease · Sprains · Sprains and Strains
Primary: Change in Numerical Pain Rating Scale — 2.9; 2.1 score on a scale
Phase 1 N=23 A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
B-cell Lymphoma
Primary: Number of Deaths Due to Adverse Events (AEs) — 1; 0 Participants
N/A N=41 Self-Management of Chronic Depressive Symptoms in Pregnancy
Depression
Primary: Recruitment Data — 41 Participants
N/A N=28 Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy
Non-small Cell Lung Cancer
Primary: Incidence of All Adverse Drug Reactions (ADRs) in Nintedanib and Docetaxel Treated Patients — 17.9 Patients per 100 patient years